Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.

NCT01678963 is registered in ClinicalTrials.gov with Ohr Pharmaceutical Inc. as lead sponsor.

NCT NCT01678963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01678963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Lead sponsor
Ohr Pharmaceutical Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
March 31, 2015
Enrollment
142 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age related macular degeneration